Tab Application Banner
  • Users Online: 236
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2015  |  Volume : 10  |  Issue : 5  |  Page : 54-58

ANCA-associated vasculitis - Should we change the standard of care?


1 Rheumatology, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, UK
2 Rheumatology, Norfolk & Norwich University Hospital NHS Foundation Trust, Norwich, UK; Norwich Medical School, University of East Anglia, Norwich, UK
3 Rheumatology, Norfolk & Norwich University Hospital NHS Foundation Trust, Norwich, UK

Correspondence Address:
Chetan Mukhtyar
Rheumatology, Norfolk & Norwich University Hospital NHS Foundation Trust, Norwich, UK

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.injr.2015.08.003

Rights and Permissions

Collaborative clinical trials over the last 25 years have revolutionised the care of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This has led to production of management recommendations and standards of care. This paper reviews the existing standards and the recent evidence that has fed further evolution of standards of care. Pattern recognition remains vital to early diagnosis and therefore initiation treatment. While cyclophosphamide remains the treatment of choice, the advent of rituximab has been shown to be beneficial to patients with relapsing disease. It may be safer in young females and those with a risk of urothelial cancers. Methotrexate and mycophenolate mofetil may not be as good as previously thought for inducing remission. Azathioprine and rituximab are the standards for remission maintenance. There have been recent changes to the nomen- clature of vasculitides. It is possible that these will continue to evolve over time to make them more meaningful and inform treatment and prognosis. In the absence of gold- standard biomarkers, we discuss the role of ANCA and histopathology, especially in the Indian setting. Follow-up and monitoring of these patients should include structured evaluation using validated clinical tools, assessing cardiovascular risk, vigilance for infec- tions and other co-morbidities due to exposure to glucocorticoids and immunosuppression.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed820    
    Printed9    
    Emailed0    
    PDF Downloaded189    
    Comments [Add]    

Recommend this journal